RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Scancell Holdings - Stock

Scancell Holdings Market capitalization 2024

Scancell Holdings Market capitalization

90.82 M GBP

Ticker

SCLP.L

ISIN

GB00B63D3314

WKN

A1JZ3D

In 2024, Scancell Holdings's market cap stood at 90.82 M GBP, a -2.37% increase from the 93.03 M GBP market cap in the previous year.

The Scancell Holdings Market capitalization history

YEARREVENUE (undefined GBP)GROSS MARGIN (%)NET INCOME (undefined GBP)
2026e---14,110.45
2025e---14,168.28
2024e---16,858.21
20235.2790,13-11,940
2022---4,570
2021---15,480
2020---5,510
2019---5,630
2018---4,190
2017---3,540
2016---2,580
2015---2,410
2014---2,220
2013---1,900
2012--560
2011---1,650
2010---1,740
2009---790
2008---410
20072.18217,89890
20060.0315833,33-640
20050.0147500,00-1,050

Scancell Holdings Aktienanalyse

What does Scancell Holdings do?

Scancell Holdings PLC is a biotechnology company specializing in the development of immunotherapies for cancer. The company was founded in 1997 and is headquartered in Nottingham, United Kingdom. Scancell's goal is to improve the lives of patients with cancer by developing innovative therapies that selectively activate the body's immune system. Scancell's business model is based on the research, development, and commercialization of immunotherapies. The company has developed a platform technology called Modified Vaccinia Ankara (MVA), which is a widely used virus in vaccine research and development. Scancell uses this platform technology to develop vaccines that selectively activate the immune system against cancer cells. The company works closely with academic partners and other biotech companies. The company has two main divisions: Scancell Immunotherapy and Scancell Biotherapeutics. Under the Scancell Immunotherapy division, the company develops cancer vaccines. Scancell is actively working on the development of two main products: SCIB1 and Modi-1. SCIB1 is an immunotherapy based on a DNA-based vaccine that activates the immune system to attack cancer cells. This vaccine has been studied in various clinical trials and has shown promising results. SCIB1 has been tested in a Phase II study on patients with advanced melanoma and has triggered a strong immune response in most patients. The company is now working on further developing SCIB1 in clinical trials. Modi-1 is an immunotherapy based on a novel technology called Modified T-cells. These are engineered T-cells that compel the immune system to recognize and attack cancer cells. Modi-1 is still in the development phase and has not yet been tested in clinical trials. Under the Scancell Biotherapeutics division, the company develops antibodies for cancer treatment. The company focuses on developing antibodies that target specific cancer antigens. Scancell has already developed several promising antibody candidates, including AvidiMabTM, an antibody candidate against the CD98 receptor, which is overexpressed in many cancer cells. Scancell is currently listed on the London Stock Exchange and has a market capitalization of around £250 million. The company also has a strong pipeline of products in development and is actively working to realize their potential. Scancell has a strong partnership with AstraZeneca, one of the world's largest pharmaceutical companies, to support its research and development activities. In summary, Scancell is an emerging biotech company specializing in the development of immunotherapies for cancer. The company has a strong pipeline of products in development and works closely with leading scientists and academic institutions. Scancell is a promising company that offers exciting opportunities for both investors and patients. Scancell Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Scancell Holdings's Market Capitalization

Scancell Holdings's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Scancell Holdings's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Scancell Holdings's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Scancell Holdings’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Scancell Holdings Stock

What is the current Scancell Holdings market capitalization?

The current market capitalization of Scancell Holdings is 90.82 M GBP.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Scancell Holdings.

How has the market capitalization of Scancell Holdings developed in recent years?

The market capitalization of Scancell Holdings has increased/decreased by -2.37% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Scancell Holdings?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Scancell Holdings?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Scancell Holdings have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Scancell Holdings pay?

Over the past 12 months, Scancell Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Scancell Holdings is expected to pay a dividend of 0 GBP.

What is the dividend yield of Scancell Holdings?

The current dividend yield of Scancell Holdings is .

When does Scancell Holdings pay dividends?

Scancell Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Scancell Holdings?

Scancell Holdings paid dividends every year for the past 0 years.

What is the dividend of Scancell Holdings?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Scancell Holdings located?

Scancell Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Scancell Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Scancell Holdings from 6/26/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Scancell Holdings pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Scancell Holdings in the year 2023?

In the year 2023, Scancell Holdings distributed 0 GBP as dividends.

In which currency does Scancell Holdings pay out the dividend?

The dividends of Scancell Holdings are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Scancell Holdings

Our stock analysis for Scancell Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Scancell Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.